<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7200043\results\search\drugs\results.xml">
  <result pre="Prospective observational study on the pharmacokinetic properties of the Irrua" exact="ribavirin" post="regimen used in routine clinical practice in patients with"/>
  <result pre="care and the broad-spectrum antiviral agent ribavirin. However, evidence for" exact="ribavirin" post="efficacy in patients with LF is poor and pharmacokinetic"/>
  <result pre="not available. Irrua Specialist Teaching Hospital (ISTH) developed an intravenous" exact="ribavirin" post="regimen different to the WHO recommendation. Apart from a"/>
  <result pre="this study is to characterise the PK of the Irrua" exact="ribavirin" post="regimen. Methods and analysis This prospective, observational clinical study"/>
  <result pre="observational clinical study will assess PK properties of the Irrua" exact="ribavirin" post="regimen on routinely ribavirin-treated patients with LF at ISTH,"/>
  <result pre="The primary objective is to describe classical PK parameters for" exact="ribavirin" post="(maximum plasma drug concentration, time to maximum plasma drug"/>
  <result pre="doses on day 1, day 4 and day 10 of" exact="ribavirin" post="treatment. Ribavirin plasma concentrations will be determined using liquid"/>
  <result pre="and limitations of this study Pharmacological analysis of the Irrua" exact="ribavirin" post="regimen will provide pharmacokinetic data on intravenous ribavirin treatment,"/>
  <result pre="the Irrua ribavirin regimen will provide pharmacokinetic data on intravenous" exact="ribavirin" post="treatment, the current standard treatment in patients with Lassa"/>
  <result pre="than in untreated controls.16 17 The mode of action of" exact="ribavirin" post="against LASV is not clear. Recently, it has been"/>
  <result pre="Recently, it has been shown with other RNA viruses that" exact="ribavirin" post="can be incorporated into the RNA strand leading to"/>
  <result pre="lethal mutagenesis or error catastrophe. Evidence for the currently recommended" exact="ribavirin" post="treatment (30 mg/kg loading dose followed by 15 mg/kg every 6 hours"/>
  <result pre="data exist about the rational for this dose, the achieved" exact="ribavirin" post="blood levels under this dose or the efficacy and"/>
  <result pre="scientific evidence is still largely lacking behind. PK assessments of" exact="ribavirin" post="are only available for different dosing regimens used for"/>
  <result pre="regimens used for hepatitis C.25 The multiple dose half-life of" exact="ribavirin" post="is estimated to be approximately 300 hours (12.5 days), which"/>
  <result pre="with LF in any institution in Nigeria, ISTH developed a" exact="ribavirin" post="regimen different from the WHO recommendation which is here"/>
  <result pre="which is here referred to as ‘Irrua regimen’ or ‘Irrua" exact="ribavirin" post="treatment regimen’.27 Apart from a higher loading dose and"/>
  <result pre="as the study by McCormick et al demonstrated efficacy of" exact="ribavirin" post="in reducing the fatality rate of LF; ribavirin also"/>
  <result pre="efficacy of ribavirin in reducing the fatality rate of LF;" exact="ribavirin" post="also increases survival in in vivo animal models of"/>
  <result pre="experience during the last decade, the standard Irrua regimen of" exact="ribavirin" post="is postulated to be efficacious. Yet it is easier"/>
  <result pre="However, to our knowledge, the PK properties of the Irrua" exact="ribavirin" post="regimen have never been described. It is not known"/>
  <result pre="this prospective observational study we aim to obtain evidence on" exact="ribavirin" post="PKs in patients who receive the Irrua ribavirin regimen"/>
  <result pre="evidence on ribavirin PKs in patients who receive the Irrua" exact="ribavirin" post="regimen as standard of care at ISTH. The Irrua"/>
  <result pre="of care at ISTH. The Irrua regimen entails the following" exact="ribavirin" post="dosages for intravenous use: Start dose (day 1): 100 mg/kg;"/>
  <result pre="for further clinical studies studying the efficacy and safety of" exact="ribavirin" post="and provide the possibility to compare the Irrua regimen"/>
  <result pre="This will serve as basis for further dose optimisation of" exact="ribavirin" post="helping to further ameliorate the management of patients with"/>
  <result pre="LF. Primary research question What are the PK properties of" exact="ribavirin" post="administered as per the Irrua ribavirin treatment regimen to"/>
  <result pre="the PK properties of ribavirin administered as per the Irrua" exact="ribavirin" post="treatment regimen to patients with LF? Study objectives General"/>
  <result pre="of this study is to describe the PK properties of" exact="ribavirin" post="when administered in routine care under the Irrua dosing"/>
  <result pre="Specific objectives Primary objective Describe the classical PK parameters for" exact="ribavirin" post="(maximum plasma drug concentration (Cmax), time to maximum plasma"/>
  <result pre="distribution (Vd)) in patients with LF treated with the Irrua" exact="ribavirin" post="regimen. Secondary objectives Examine the clinical, haematological, biochemical parameters"/>
  <result pre="haematological, biochemical parameters of the patients and correlate them with" exact="ribavirin" post="blood levels. Study the kinetics of LASV loads in"/>
  <result pre="be conducted to assess the PK properties of the Irrua" exact="ribavirin" post="regimen on routinely ribavirin-treated patients with LF at the"/>
  <result pre="consent. Primary end point PK parameters of the routine care" exact="ribavirin" post="regimen at ISTH. Secondary end points Viral kinetics in"/>
  <result pre="points Viral kinetics in patients routinely treated with the Irrua" exact="ribavirin" post="regimen. LASV genome changes under the Irrua ribavirin regimen."/>
  <result pre="the Irrua ribavirin regimen. LASV genome changes under the Irrua" exact="ribavirin" post="regimen. Study site The Lassa Unit of the ISTH"/>
  <result pre="pregnant within the upcoming 3 months. Patients who already received" exact="ribavirin" post="within the last 7 days. Concomitant administration of didanosine"/>
  <result pre="received ribavirin within the last 7 days. Concomitant administration of" exact="didanosine" post="and other contraindicated concomitant medication. Enrolment Recruitment of patients"/>
  <result pre="study participation. Furthermore, children and pregnant women do not receive" exact="ribavirin" post="intravenously but orally and are therefore not eligible for"/>
  <result pre="with different treatments or treatment regimens (eg, the WHO recommended" exact="ribavirin" post="regimen) will be performed. The potential bias in this"/>
  <result pre="contraindicating the collection of blood or premature termination of intravenous" exact="ribavirin" post="administration due to clinical improvement and switch to oral"/>
  <result pre="doses on day 1, day 4 and day 10 of" exact="ribavirin" post="treatment. Additionally, it will be collected during screening before"/>
  <result pre="Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Germany). There," exact="ribavirin" post="plasma concentrations will be determined using liquid chromatography coupled"/>
  <result pre="with the goal to characterise the typical PK parameters of" exact="ribavirin" post="and PK variability. Linear as well as non-linear compartmental"/>
  <result pre="in PK. In particular, we will analyse the changes in" exact="ribavirin" post="concentration and haemoglobin levels, ALT/GPT and uric acid. These"/>
  <result pre="acid. These are prognostic markers for survival, for metabolism of" exact="ribavirin" post="and for potential side effects and toxicity (eg, haemolysis)."/>
  <result pre="on changes in longitudinal biological parameters as described previously for" exact="ribavirin" post="in patients with HCV.34 PK-PD modelling The PK data"/>
  <result pre="to evaluate the effect (or the lack of effect) of" exact="ribavirin" post="monotherapy on the Lassa viral kinetics. Semi-mechanistic modelling of"/>
  <result pre="StephenELEnhanced treatment of Lassa fever by immune plasma combined with" exact="ribavirin" post="in cynomolgus monkeys. J Infect Dis1984;149:420–7. 10.1093/infdis/149.3.4206715898 18StephenEL, JahrlingPBExperimental"/>
  <result pre="A2001;98:6895–900. 10.1073/pnas.11108559811371613 21CrottyS, MaagD, ArnoldJJ, et al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med2000;6:1375–9. 10.1038/8219111100123 22McCormickJB,"/>
  <result pre="Infect Dis2019;87:15–20. 10.1016/j.ijid.2019.07.01531357056 24collab: World Health OrganisationApplication for inclusion of" exact="ribavirin" post="in the WHO model list of essential medicines2006. 25PrestonSL,"/>
  <result pre="medicines2006. 25PrestonSL, DrusanoGL, GlueP, et al.Pharmacokinetics and absolute bioavailability of" exact="ribavirin" post="in healthy volunteers as determined by stable-isotope methodology. Antimicrob"/>
  <result pre="LüdtkeA, et al.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model of Lassa fever."/>
  <result pre="10.1093/infdis/jiv52226531247 29JinR, FosslerMJ, McHutchisonJG, et al.Population pharmacokinetics and pharmacodynamics of" exact="ribavirin" post="in patients with chronic hepatitis C genotype 1 infection."/>
  <result pre="Negl Trop Dis2017;11:e0005389. 10.1371/journal.pntd.000538928231247 32LoregianA, ScarpaMC, PagniS, et al.Measurement of" exact="ribavirin" post="and evaluation of its stability in human plasma by"/>
 </snippets>
</snippetsTree>
